why choose us

First received: December 19, 2022

Clinical Trial: A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cystic Fibrosis

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.

Read more